Safety and Efficacy of Hydrus and I-Stent inject combined with Phacoemulsification in Primary Open Angle Glaucoma Patients: 2 year follow up study
Article Sidebar
Downloads
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
http://orcid.org/0000-0003-2797-4174
Tarun Sharma, FRCSEd
http://orcid.org/0000-0003-3507-5187
Abstract
Aims: To compare the safety and efficacy of phacoemulsification combined with two individual kinds of trabecular bypass micro-stent device insertion. This study compares Phacoemulsification with Hydrus stent versus phacoemulsification combined with I-Stent inject W in patients with medically uncontrolled primary open-angle glaucoma (POAG).
Material and Methods: A retrospective comparative case series.
Results: Eighty eyes of 75 patients with 2 years completed follow-up after combined phacoemulsification with trabecular by-pass stent (s) were included. Forty eyes of 37 patients had Hydrus stent (Hydrus Group-PH) and the other 40 eyes of 38 patients had I-stent inject W (I-stent Group-Pi) insertion combined with phacoemulsification and intraocular lens implantation. Patient demographics and preoperative characteristics of the two groups studied are comparable. A post-operative decrease of 20 percentage or more in the IOP was achieved in 33 eyes (82.5%) in PH group and 30 eyes (75%) in Pi group (p=0.57). The Hydrus group (PH) had a post-operative reduction in the mean number of medications in 22 eyes (55%) in comparison to 18 eyes (45%) in the I-stent group (Pi). Second stage trabeculectomy was avoided in 31 eyes (77.5%) in the Hydrus group and 27 eyes (67.5%). There was no significant difference in rate of complications between two groups.
Conclusion: Both Hydrus stent and I-stent inject W combined with phacoemulsification and intra-ocular lens implantation, are efficacious and safe for treating patients with medically uncontrolled mild and moderate primary open-angle glaucoma (POAG). The reduction in the mean IOP and in the mean number of post-operative glaucoma medications was higher for the patients in Hydrus stent group than in I-stent inject W group.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Purola PKM, Nättinen JE, Ojamo MUI, Rissanen HA, Gissler M, Koskinen SVP, Uusitalo HMT. Prevalence and 11-Year Incidence of Cataract and Cataract Surgery and the Effects of Socio-Demographic and Lifestyle Factors. Clin Ophthalmol. 2022 Apr 20;16:1183-1195.
3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120: 1268-1279.
4. Sharma O, Abdulla D, King A, Chakrabarti M, Sharma T. Role of minimally invasive glaucoma surgery in the management of chronic open-angle glaucoma. Sci Rep. 2021 Nov 2;11(1):21432.
5. Ahmed et al.: A prospective randomized trial comparing Hydrus and iStent micro-invasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study (Ophthalmology. 2020; 127:52–61)
6. Grant WM. Further studies on facility of flow through the trabecular meshwork. Arch Ophthalmol. 1958; 60:523e533.
7. Maepea O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm’s canal in monkeys. Exp Eye Res. 1992;54: 879e883.
8. Seiler T, Wollensak J. The resistance of the trabecular meshwork to aqueous humor outflow. Graefes Arch Clin Exp Ophthalmol. 1985; 223:88e91.
9. Holmes, D.P.; Clement, C.I.; Nguyen, V.; Healey, P.R.; Lim, R.; White, A.; Yuen, J.; Lawlor, M. Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery. Clin. Exp. Ophthalmol. 2022, 50, 303–311.
10. Hu, R.; Guo, D.; Hong, N.; Xuan, X.; Wang, X. Comparison of Hydrus and iStent microinvasive glaucoma surgery implants in combination with phacoemulsification for treatment of open-angle glaucoma: Systematic review and network meta-analysis.BMJ Open 2022, 15, 12.
11. Wellik, S.R.; Dale, E.A. A review of the iStent trabecular micro-bypass stent: Safety and efficacy. Clin. Ophthalmol. 2015, 9, 677–684.
12. E.R.; Katz, L.J.; Wells, J.M.; Giamporcaro, J.E. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up. J. Cataract Refract. Surg. 2012, 38, 1339–1345.
13. Tan, S.Z.; Au, L. Manchester iStent study: 3-year results and cost analysis. Eye 2016, 30, 1365–1370.
14. Fea, A.M.; Consolandi, G.; Zola, M.; Pignata, G.; Cannizzo, P.; Lavia, C.; Rolle, T.; Grignolo, F.M. Micro-Bypass Implantation for Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up. J. Ophthalmol. 2015, 2015, 795357.
15. Fea, A.M.; Ahmed, I.I.; Lavia, C.; Mittica, P.; Consolandi, G.; Motolese, I.; Pignata, G.; Motolese, E.; Rolle, T.; Frezzotti, P. Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: One year results. Clin. Exp. Ophthalmol. 2017, 45, 120–127.
16. Hodapp E, Parrish RK II, Anderson DR. Clinical decisions in glaucoma. St Louis: The CV Mosby Co; 1993. pp. 52–61.
17. Anand A, Negi S, Khokhar S, Kumar H, Gupta SK, Murthy GV, Sharma TK. Role of early trabeculectomy in primary open-angle glaucoma in the developing world. Eye (Lond). 2007 Jan;21(1):40-5.
18. Agarwal HC, Sharma TK, Sihota R, Gulati V. Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy. J Postgrad Med. 2002 Apr-Jun;48(2):92-6.
19. Sihota R, Sharma T, Agarwal HC. Intraoperative mitomycin C and the corneal endothelium. Acta Ophthalmol Scand. 1998 Feb;76(1):80-2.
20. Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121, 2081–2090 (2014).
21. King, A., Azuara-Blanco, A. & Tuulonen, A. Glaucoma. BMJ 346, f3518 (2013).
22. Jea SY, Mosaed S, Vold SD, Rhee DJ. Effect of a failed trabectome on subsequent trabeculectomy. J Glaucoma. 2012;21(2):71e75
23. Samuelson, T.W.; Chang, D.F.; Marquis, R.; Flowers, B.; Lim, K.S.; Ahmed, I.I.K.; Jampel, H.D.; Aung, T.; Crandall, A.S.; Singh, K.; et al. A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology 2019, 126, 29–37.
24. Otarola, F.; Virgili, G.; Shah, A.; Hu, K.; Bunce, C.; Gazzard, G. Ab interno trabecular bypass surgery with Schlemm’s canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst. Rev. 2020, 9, 3.